Figure 1From: Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and ChlorthalidoneKaplan-Meier estimates for cumulative mortality for hospitalized heart failure cases in the chlorthalidone and doxazosin groups (RR 0.96, 95% CI, 0.67–1.38; P = 0.84)Back to article page